Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2/3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 295Carcinoma, Non-Small-Cell Lung 160Lung Neoplasms 89Breast Neoplasms 84Urinary Bladder Neoplasms 83Cholangiocarcinoma 58Neoplasms 53Neoplasm Metastasis 51Ovarian Neoplasms 45Biliary Tract Neoplasms 45Lymphoma, Large B-Cell, Diffuse 32Lymphoma 30Sarcoma 29Hodgkin Disease 28Recurrence 26Nasopharyngeal Carcinoma 26Gallbladder Neoplasms 26Carcinoma, Transitional Cell 26Adenocarcinoma 22Triple Negative Breast Neoplasms 20Fallopian Tube Neoplasms 20Bile Duct Neoplasms 20Adenocarcinoma of Lung 20Carcinoma, Renal Cell 17Carcinoma, Ovarian Epithelial 16Urethral Neoplasms 15Lymphoma, Non-Hodgkin 15Colorectal Neoplasms 14Leiomyosarcoma 13Kidney Neoplasms 13

Interventions

Fluorouracil 4Oxaliplatin 3Capecitabine 3toripalimab 2dehydroftorafur 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Leucovorin 2Biopsy 2tremelimumab 1trametinib 1tislelizumab 1temoporfin 1sacituzumab govitecan 1lenvatinib 1gemcitabine-oxaliplatin regimen 1durvalumab 1binimetinib 1Stents 1Sorafenib 1Radiosurgery 1Hydroxychloroquine 1Gemcitabine 1Erlotinib Hydrochloride 1Cisplatin 13-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Klatskin Tumor × Gemcitabine × Clear all
NCT07030140 2026-05-01

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡